BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.82%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.17B
AUM Growth
+$6.17B
(+0.29%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
39.22%
Holding
177
New
11
Increased
57
Reduced
71
Closed
15
Top Buys
| 1 |
Evolent Health
EVH
|
$28.3M |
| 2 |
Exact Sciences
EXAS
|
$19.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
Abbott
ABT
|
$15.7M |
| 5 |
Inspire Medical Systems
INSP
|
$14.8M |
Top Sells
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$36.5M |
| 2 |
Insmed
INSM
|
$36.2M |
| 3 |
argenx
ARGX
|
$32M |
| 4 |
Charles River Laboratories
CRL
|
$31.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$30.5M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Industrials | 0.04% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AUTL
151
Autolus Therapeutics
AUTL
$383M
| $151K | ﹤0.01% |
41,500
+9,000
| +28% | +$32.7K |
|
152
NewAmsterdam Pharma
NAMS
$2.8B
| $128K | ﹤0.01% |
+7,700
| New | +$128K |
|
153
Veracyte
VCYT
$2.41B
| $123K | ﹤0.01% |
+3,600
| New | +$123K |
|
154
Agilent Technologies
A
$35.5B
| $114K | ﹤0.01% |
769
+65
| +9% | +$9.65K |
|
155
Oracle
ORCL
$628B
| $106K | ﹤0.01% |
624
+53
| +9% | +$9.03K |
|
156
NVIDIA
NVDA
$4.15T
| $87K | ﹤0.01% |
716
+61
| +9% | +$7.41K |
|
157
Microsoft
MSFT
$3.76T
| $83.5K | ﹤0.01% |
194
+15
| +8% | +$6.45K |
|
158
Qualcomm
QCOM
$170B
| $72.6K | ﹤0.01% |
427
+36
| +9% | +$6.12K |
|
159
Mettler-Toledo International
MTD
$26.1B
| $61.5K | ﹤0.01% |
41
+1
| +3% | +$1.5K |
|
160
OmniAb
OABI
$219M
| $48.5K | ﹤0.01% |
11,456
| – | – |
|
161
Labcorp
LH
$22.8B
| $46K | ﹤0.01% |
206
+16
| +8% | +$3.58K |
|
|
TEM
162
Tempus AI, Inc. Class A Common Stock
TEM
$13.3B
| $29.2K | ﹤0.01% |
516
-4,484
| -90% | -$254K |
|
163
Apple
AAPL
$3.54T
| – | – |
-2,200
| Closed | -$463K |
|
164
Alkermes
ALKS
$4.95B
| – | – |
-18,000
| Closed | -$434K |
|
165
AtriCure
ATRC
$1.73B
| – | – |
-212,559
| Closed | -$4.84M |
|
|
BCYC
166
Bicycle Therapeutics
BCYC
$492M
| – | – |
-16,000
| Closed | -$324K |
|
167
C4 Therapeutics
CCCC
$182M
| – | – |
-57,600
| Closed | -$266K |
|
168
Dynavax Technologies
DVAX
$1.19B
| – | – |
-27,558
| Closed | -$309K |
|
169
89bio
ETNB
$1.37B
| – | – |
-24,700
| Closed | -$198K |
|
170
4D Molecular Therapeutics
FDMT
$302M
| – | – |
-15,700
| Closed | -$330K |
|
171
Outset Medical
OM
$245M
| – | – |
-50,853
| Closed | -$2.94M |
|
172
Teladoc Health
TDOC
$1.37B
| – | – |
-272,798
| Closed | -$2.67M |
|
173
West Pharmaceutical
WST
$17.9B
| – | – |
-520
| Closed | -$171K |
|
|
GRAL
174
GRAIL, Inc. Common Stock
GRAL
$1.17B
| – | – |
-7,266
| Closed | -$112K |
|
|
NVRO
175
DELISTED
NEVRO CORP.
NVRO
| – | – |
-135,235
| Closed | -$1.14M |
|